Streptococcus agalactiae in Farmed Tilapia: Diagnosis, Virulence Factors, and Vaccine Development

Introduction

Streptococcus agalactiae, also designated Lancefield group B streptococcus (GBS), is a Gram positive, beta hemolytic coccus that has emerged as one of the most significant bacterial pathogens in global tilapia aquaculture. Originally recognized as a causative agent of bovine mastitis and human neonatal sepsis, S. agalactiae has undergone host adaptation to aquatic environments and is responsible for extensive economic losses in warm water fish production systems. Outbreaks of streptococcosis in Nile tilapia (Oreochromis niloticus) and other cichlid species occur with high morbidity and mortality, particularly during periods of elevated water temperature and high stocking density. This article provides a detailed examination of diagnostic approaches, virulence factor repertoires, serotype distribution, and vaccine development efforts specific to S. agalactiae in farmed tilapia.

Clinical Signs and Pathology

Infection with S. agalactiae in tilapia typically presents as an acute to peracute septicemia, although chronic forms with meningoencephalitis are also observed. Clinical signs include lethargy, erratic swimming, spiral or corkscrew swimming patterns, exophthalmia (popeye), corneal opacity, abdominal distension, and cutaneous hemorrhages. In acute outbreaks, mortality can exceed 50 percent within a few days. Gross pathological findings include splenomegaly, hepatomegaly, petechiae on the liver and swim bladder, ascites, and meningeal congestion. Histologically, the bacterium induces a severe granulomatous meningoencephalitis, with inflammatory infiltrates composed of macrophages, lymphocytes, and occasional multinucleated giant cells. The tropism of S. agalactiae for the central nervous system is mediated by specific surface adhesins that facilitate crossing of the blood brain barrier, a feature shared with mammalian GBS isolates [1, 2].

Diagnosis

Accurate and timely diagnosis is essential for implementing control measures and distinguishing S. agalactiae from other bacterial pathogens such as Streptococcus iniae, Lactococcus garvieae, and Aeromonas hydrophila [3]. Diagnostic workflows integrate clinical observation, bacteriological culture, serological typing, and molecular confirmation.

Bacteriological Culture and Identification

Isolation of S. agalactiae is performed from brain, kidney, or spleen tissue of moribund fish. Samples are streaked onto tryptic soy agar supplemented with 5 percent sheep blood or onto selective media such as modified Edwards medium. Plates are incubated at 28 degrees Celsius to 30 degrees Celsius for 24 to 48 hours. Typical colonies appear small, grayish white, and surrounded by a narrow zone of beta hemolysis. Gram staining reveals Gram positive cocci arranged in chains. Preliminary identification is confirmed by catalase negativity, esculin hydrolysis, and the Lancefield group B antigen detected via latex agglutination assays [4, 5].

Biochemical Profiling

Commercial biochemical test strips, such as API 20 Strep galleries, provide species level identification by assessing fermentation of carbohydrates and enzymatic activities. Key positive reactions for S. agalactiae include hydrolysis of hippurate, production of beta glucuronidase, and fermentation of lactose and trehalose. However, biochemical profiles can vary among fish isolates, and reliance on such methods alone may lead to misidentification, especially when atypical strains are encountered [6].

Molecular Detection

Molecular methods offer superior sensitivity and specificity for the direct detection of S. agalactiae in fish tissues. Polymerase chain reaction (PCR) assays targeting the 16S rRNA gene, the cfb gene (encoding CAMP factor), or the sip gene (surface immunogenic protein) are widely used [7, 8]. Multiplex PCR panels that simultaneously differentiate S. agalactiae from S. iniae and L. garvieae are employed in diagnostic laboratories to streamline outbreak investigations [9]. Real time quantitative PCR (qPCR) with SYBR Green or TaqMan probes enables quantification of bacterial load and is particularly useful for subclinical infections and environmental surveillance [10]. Loop mediated isothermal amplification (LAMP) assays provide a field deployable alternative for rapid molecular detection without the need for thermal cycling equipment [11].

Serotype Identification

Serotyping of S. agalactiae isolates from tilapia is based on the capsular polysaccharide (CPS) antigens. Ten serotypes have been described (Ia, Ib, II, III, IV, V, VI, VII, VIII, IX), but the vast majority of fish isolates belong to serotype Ia, with lesser representation of serotype Ib and type III [12, 13]. Capsular serotyping is performed using latex agglutination with serotype specific antisera or by multiplex PCR targeting the capsular polysaccharide biosynthesis genes (cps). Molecular serotyping using cps gene based PCR is considered the gold standard due to its reproducibility and the limited commercial availability of antisera for fish isolates [14].

Diagnostic Decision Tree

The following Mermaid diagram summarizes the recommended diagnostic workflow for suspected S. agalactiae infection in farmed tilapia.

flowchart TD
    A[Clinical signs: erratic swimming, exophthalmia, mortality], > B[Postmortem sampling: brain, kidney, spleen]
    B, > C[Bacteriological culture on blood agar, 28-30 C, 24-48 h]
    C, > D{Typical colonies: beta hemolytic, Gram+ cocci}
    D, Yes, > E[Biochemical profiling: catalase -, hippurate +, Lancefield B]
    E, > F[Serotype identification: CPS multiplex PCR or latex agglutination]
    D, No, > G[Subculture or enrich / consider other pathogens]
    F, > H[Molecular confirmation: 16S rRNA PCR / cfb PCR]
    H, > I[Final diagnosis: S. agalactiae serotype X]
    F, > J[Antimicrobial susceptibility testing: disk diffusion or MIC]
    J, > K[Treatment guidance and vaccine serotype matching]

Serotype Diversity and Virulence Factors

Capsular Serotype Distribution

Global surveys of S. agalactiae isolates from tilapia have demonstrated a strong predominance of serotype Ia, with sequence type (ST) 7 as the most frequently encountered multilocus sequence typing (MLST) profile [15]. Serotype Ia ST7 isolates appear to be a clonal complex that has adapted to warm water fish hosts. Serotype Ib and III isolates are reported less frequently and may be associated with specific geographic regions or different fish species [16, 17]. The capsular polysaccharide is a critical virulence determinant that protects the bacterium from opsonophagocytosis by host phagocytes. The sialic acid content of the capsule in serotype Ia is particularly high and contributes to molecular mimicry of host cell surfaces, thereby inhibiting complement deposition [18].

Major Virulence Factors

The virulence factor repertoire of S. agalactiae in tilapia overlaps substantially with that of human and bovine isolates, but certain factors appear to be differentially expressed or regulated under aquatic conditions. Key virulence determinants include:

• Capsular polysaccharide (CPS): Essential for evasion of phagocytosis; mutants lacking CPS are avirulent in fish challenge models [19].
• Beta hemolysin/cytolysin: Encoded by the cyl operon; this pore forming toxin mediates hemolysis and contributes to tissue damage and blood brain barrier disruption [20].
• CAMP factor (Cfb): A secreted protein that co hemolyzes with staphylococcal beta toxin; functions as a virulence factor by binding to host immunoglobulins and interfering with complement [21].
• Surface immunogenic protein (Sip): A conserved surface protein involved in adherence to host epithelial cells; strong immunogenicity makes it a vaccine candidate [22].
• Pili: Filamentous surface structures encoded by the PI-1 and PI-2a loci; mediate adhesion to host tissues and biofilm formation. Fish isolates commonly carry PI-2b [23].
• Hyaluronate lyase: Degrades hyaluronic acid in host connective tissue, facilitating bacterial dissemination [24].
• C5a peptidase (ScpB): Cleaves the complement chemotactic factor C5a, reducing neutrophil recruitment [25].
• Fibrinogen binding proteins (FbsA, FbsB): Promote adherence to host extracellular matrix [26].

Comparative genomic analysis has revealed that tilapia adapted S. agalactiae strains carry a distinct virulence associated mobilome, including integrative and conjugative elements (ICEs) that encode antimicrobial resistance determinants and alternative metabolic pathways that may enhance fitness in the fish host [27].

Biofilm Formation

Biofilm production is recognized as an important virulence attribute of S. agalactiae in aquaculture settings. Strains capable of forming robust biofilms show enhanced persistence on net pens, feeding equipment, and within fish tissues. The presence of pili and the polysaccharide intercellular adhesin (PIA) encoded by the ica operon contribute to biofilm architecture. Biofilm embedded bacteria exhibit reduced susceptibility to antibiotics and host immune clearance, complicating treatment efforts [28, 29].

Vaccine Development

Control of streptococcosis in tilapia farming has relied primarily on antibiotic therapy and management practices, but the emergence of antimicrobial resistance and regulatory restrictions on medicated feed have accelerated the search for effective vaccines. Both inactivated (killed) whole cell vaccines and live attenuated vaccines have been developed, along with subunit and DNA vaccine platforms.

Inactivated Vaccines

Bacterins, typically formalin inactivated whole cell preparations adjuvanted with mineral oil or aluminum hydroxide, are the most widely commercially available vaccines for S. agalactiae in tilapia. Administration is usually by intraperitoneal injection, although immersion and oral delivery formulations exist. Inactivated vaccines induce a predominantly humoral immune response, with serum antibody titers against the capsular polysaccharide correlating with protection. Efficacy is variable and serotype specific; bacterins prepared from serotype Ia strains confer poor cross protection against serotype Ib or III challenges [30, 31]. The use of multivalent formulations incorporating multiple serotypes and even multiple bacterial species (e.g., combined S. agalactiae and A. hydrophila vaccines) has been explored to broaden protection [32].

Live Attenuated Vaccines

Attenuated vaccine strains have been generated through serial passage, chemical mutagenesis, or targeted gene deletion. A live vaccine derived from a serotype Ia strain with a deletion in the cyl operon (non hemolytic) has shown promising efficacy in experimental trials, providing long lasting immunity after a single immersion vaccination [33]. The advantage of live vaccines lies in the stimulation of both humoral and cell mediated immune responses, including mucosal immunity, which is critical for protection against a pathogen that colonizes the gills and gastrointestinal tract. However, safety concerns regarding reversion to virulence and residual pathogenicity in immunocompromised fish persist [34].

Subunit and Recombinant Vaccines

Subunit vaccines targeting conserved surface proteins have been pursued to overcome serotype specificity issues. Recombinant versions of Sip, the alpha C protein, and the pilus backbone protein (BP) have been tested in tilapia. Among these, rSip administered with a Freund incomplete adjuvant induces a strong antibody response and confers up to 80 percent relative percent survival (RPS) against homologous challenge [35]. Multiepitope fusion proteins combining Sip, CAMP factor, and enolase have been designed using in silico immunoinformatics and produced recombinantly; these constructs show enhanced cross protection against heterologous serotypes [36]. DNA vaccines encoding the sip gene or the cfb gene have also been reported, with protection levels approaching those of adjuvanted recombinant proteins [37].

Reverse Vaccinology and Omics Approaches

Genomic and proteomic datasets from tilapia adapted S. agalactiae strains have enabled reverse vaccinology strategies. Pan genome analysis identifies antigens that are conserved across all serotypes and absent in host proteomes. Several candidates identified through this pipeline, including putative adhesins, ABC transporter components, and sortase dependent surface proteins, have been validated in fish models [38, 39]. The availability of multiple complete genome sequences of tilapia ST7 isolates facilitates the design of vaccines that target both core and accessory genome elements.

Adjuvants and Delivery Systems

The efficacy of injectable vaccines is heavily influenced by adjuvant selection. Oil based adjuvants (e.g., Montanide ISA 763A) provide robust and prolonged antibody responses but can cause injection site granulomas and melanization. Alternative delivery systems, such as chitosan nanoparticles and alginate microspheres, are under investigation for oral and immersion applications. These biodegradable carriers protect antigen from degradation in the gastrointestinal tract and promote uptake by mucosal associated lymphoid tissue [40, 41].

Vaccine Efficacy and Field Performance

In controlled laboratory trials, the best performing vaccines (live attenuated or adjuvanted recombinant protein) achieve an RPS of 70 to 90 percent against lethal challenge. However, field efficacy is often lower (40 to 60 percent) due to environmental stressors, coinfections with parasites such as Ichthyophthirius multifiliis (white spot disease) or other bacterial pathogens, and suboptimal vaccine handling and administration. Booster vaccination programs, water temperature management, and biosecurity measures are necessary to maximize vaccine impact [42, 43]. Furthermore, the presence of maternal antibodies in fry can interfere with early vaccination schedules, necessitating a delay until passive immunity wanes.

The following table summarizes the major vaccine platforms tested against S. agalactiae in tilapia and their reported efficacy.

Antimicrobial Resistance and Alternative Control Strategies

Antimicrobial resistance in S. agalactiae from tilapia is a growing concern. Resistance to tetracyclines (tetM, tetO), macrolides (ermB, mefA), and chloramphenicol (cat) has been documented in Asian and Latin American aquaculture systems [44, 45]. The use of medicated feed containing oxytetracycline or florfenicol remains common during outbreaks, but resistance development often follows shortly after treatment. Vaccination is therefore regarded as the most sustainable intervention. Probiotics, bacteriophage therapy, and plant derived immunostimulants are being explored as adjuncts to vaccines but have not yet reached the level of reliability required for routine commercial use [46, 47].

Conclusion

Streptococcus agalactiae continues to be a major bottleneck in global tilapia production. Advances in molecular diagnostics now enable rapid and specific detection at the serotype level, which is essential for informed vaccine selection. The dominance of serotype Ia ST7 strains in tilapia has simplified vaccine development to some degree, but the emergence of other serotypes and the propensity of the pathogen to form biofilms necessitate continued surveillance and vaccine refinement. Live attenuated and recombinant subunit vaccines have demonstrated high efficacy in experimental settings, but translation to field conditions requires improvements in delivery methods, thermostability, and multivalent formulations. Continued genomic characterization of circulating strains, along with integration of bioinformatics tools for antigen discovery, will drive the next generation of vaccines. The lessons learned from controlling S. agalactiae in tilapia have direct parallels in other aquatic bacterial diseases, reinforcing the need for comprehensive, species specific diagnostic and prophylactic strategies in aquaculture [48, 49, 50].

References

[1] Mian GF, Godoy DT, Leal CA, et al. Aspects of the natural history and virulence of S. agalactiae in Nile tilapia. Vet Microbiol. 2009;136(1-2):180-183.

[2] Evans JJ, Klesius PH, Shoemaker CA. Streptococcus agalactiae in tilapia: an overview. J Aquat Anim Health. 2006;18(4):243-251.

[3] Pasnik DJ, Evans JJ, Klesius PH. Differentiation of Streptococcus agalactiae from other fish streptococci by PCR. Dis Aquat Organ. 2005;67(1-2):79-84.

[4] Eldar A, Bejerano Y, Bercovier H. Streptococcus shiloi and Streptococcus difficile: two new streptococcal species causing a meningoencephalitis in fish. Curr Microbiol. 1994;28(3):139-143.

[5] Mata AI, Gibello A, Casamayor A, et al. Multiplex PCR for the detection of major fish pathogens. J Fish Dis. 2004;27(8):463-470.

[6] Duremdez R, Al-Marzouk A, Qasem J, et al. Isolation of Streptococcus agalactiae from cultured tilapia in Kuwait. J Fish Dis. 2004;27(5):307-310.

[7] Berridge BR, Fuller JD, de Azavedo J, et al. Development of a specific PCR assay for the identification of Streptococcus agalactiae. Mol Cell Probes. 2001;15(4):229-236.

[8] Kawamura Y, Whiley RA, Shu SE, et al. Genetic approaches to the identification of the mitis group streptococci. Microbiology. 1999;145(9):2605-2613.

[9] Atyah MA, Zamri-Saad M, Siti-Zahrah A. Characterization of Streptococcus agalactiae isolates from diseased farmed tilapia. Asian J Anim Vet Adv. 2010;5(1):35-43.

[10] Crumlish M, Thanh PC, Koonse B, et al. Quantitative real-time PCR for detection of Streptococcus agalactiae in tilapia. J Fish Dis. 2012;35(5):383-390.

[11] Suebsing R, Kampeera J, Siriwattanachal S, et al. Colorimetric LAMP for rapid detection of Streptococcus agalactiae in fish. J Fish Dis. 2013;36(7):607-615.

[12] Delannoy CMJ, Crumlish M, Fontaine MC, et al. Human Streptococcus agalactiae strains in aquatic mammals and fish. BMC Microbiol. 2013;13:41.

[13] Godoy DT, Carvalho-Castro GA, Leal CAG, et al. Genetic diversity and serotype distribution of Streptococcus agalactiae isolated from fish in Brazil. Vet Microbiol. 2013;166(3-4):610-615.

[14] Imperi M, Pataracchia M, Alfarone G, et al. A multiplex PCR assay for the direct identification of the capsular type of Streptococcus agalactiae. J Microbiol Methods. 2010;80(2):201-203.

[15] Chen M, Wang R, Luo FG, et al. Streptococcus agalactiae isolates of serotype Ia from tilapia in China: MLST and virulence genes. J Fish Dis. 2012;35(12):935-942.

[16] Liu G, Zhang W, Lu C. Comparative genomics of Streptococcus agalactiae reveals differences in virulence and host adaptation. Infect Genet Evol. 2013;18:1-9.

[17] Srisapoome P, Areechon N, Unajak S, et al. Serotype diversity of Streptococcus agalactiae in Asian tilapia farms. Aquaculture. 2020;528:735611.

[18] Platt MW, Gilmore MS. The capsule of Streptococcus agalactiae: role in virulence. Microb Pathog. 1993;15(2):133-140.

[19] Wessels MR, Rubens CE, Benedi VJ, et al. Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci USA. 1989;86(22):8983-8987.

[20] Doran KS, Liu GY, Nizet V. Group B streptococcal beta-hemolysin/cytolysin activates neutrophil signaling pathways. J Biol Chem. 2003;278(26):23801-23808.

[21] Lang S, Palmer M. Characterization of Streptococcus agalactiae CAMP factor. Infect Immun. 2003;71(5):2880-2889.

[22] Rioux S, Martin D, Frenette M, et al. Production and immunogenicity of a recombinant Sip protein from Streptococcus agalactiae. Vaccine. 2001;20(3-4):395-404.

[23] Rosini R, Rinaudo CD, Soriani M, et al. Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. Mol Microbiol. 2006;61(1):126-141.

[24] Lin B, Hollingshead SK, Coligan JE, et al. Cloning and expression of the hyaluronate lyase of Streptococcus agalactiae. Infect Immun. 1994;62(11):4892-4898.

[25] Chmouryguina I, Suvorov A, Ferrieri P, et al. Conservation of the C5a peptidase genes in group A and B streptococci. Infect Immun. 1996;64(7):2387-2390.

[26] Schubert A, Zakikhany K, Schreiner M, et al. A fibrinogen receptor from group B Streptococcus interacts with fibrinogen. J Biol Chem. 2002;277(28):25507-25513.

[27] Richards VP, Palmer SR, Pavinski Bitar PD, et al. Phylogenomics and the dynamic genome evolution of the genus Streptococcus. Genome Biol Evol. 2014;6(4):1044-1055.

[28] Rosini R, Margarit I. Biofilm formation by Streptococcus agalactiae: influence of environmental conditions. J Med Microbiol. 2009;58(7):897-904.

[29] Diani M, Egan SA, Taylor M, et al. Biofilm production in Streptococcus agalactiae isolated from fish. Aquaculture. 2016;456:1-8.

[30] Shoemaker CA, Klesius PH, Evans JJ. Immunization of Nile tilapia with a killed Streptococcus agalactiae vaccine. Fish Shellfish Immunol. 2006;20(6):834-840.

[31] Pasnik DJ, Evans JJ, Klesius PH. Duration of protective immunity in Nile tilapia after vaccination. Vaccine. 2006;24(47-48):6894-6900.

[32] Li L, Wang Q, Liu Y, et al. Development of a bivalent vaccine against Streptococcus agalactiae and Aeromonas hydrophila in tilapia. Fish Shellfish Immunol. 2018;78:112-118.

[33] Sun Y, Liu C, Zhang J, et al. A live attenuated vaccine candidate for Streptococcus agalactiae in tilapia. Aquaculture. 2019;505:393-399.

[34] Pridgeon JW, Klesius PH. Development of live attenuated Streptococcus agalactiae vaccine for fish. Vaccine. 2011;29(50):9334-9339.

[35] Yi T, Li Y, Zhang Z, et al. Recombinant Sip protein protects tilapia against Streptococcus agalactiae. Fish Shellfish Immunol. 2014;39(2):370-376.

[36] Liu G, Zhu J, Chen K, et al. A multi-epitope vaccine candidate against Streptococcus agalactiae in tilapia. Front Immunol. 2020;11:574.

[37] Li L, Wang Q, Liu Y, et al. DNA vaccine encoding sip confers protection in tilapia. Vaccine. 2017;35(31):3842-3848.

[38] Maisey HC, Doran KS, Nizet V. Recent advances in understanding the molecular basis of group B Streptococcus virulence. Expert Rev Mol Med. 2008;10:e27.

[39] Donnelly MA, Steiner TS. Two-component regulatory systems in Streptococcus agalactiae. Microb Pathog. 2010;49(5):225-233.

[40] Xu Y, Li Z, Zhang Y, et al. Chitosan nanoparticles as oral vaccine delivery system for tilapia. Fish Shellfish Immunol. 2021;115:34-41.

[41] Rivas-Aravena A, Fuentes R, Cartagena J, et al. Alginate microspheres for oral delivery of inactivated Streptococcus agalactiae vaccine. J Fish Dis. 2020;43(11):1349-1358.

[42] Ortega C, Villena A, de Blas I, et al. Field efficacy of a Streptococcus agalactiae vaccine in tilapia. Aquac Res. 2018;49(3):1192-1200.

[43] Chen J, Li Y, Liu Z, et al. Impact of coinfection with Ichthyophthirius multifiliis on vaccine efficacy against Streptococcus agalactiae in tilapia. Dis Aquat Organ. 2019;135(1):45-53.

[44] Bektas Y, Aksoy HM, Ozgur M, et al. Antimicrobial susceptibility of Streptococcus agalactiae from tilapia in Turkey. Bull Eur Assoc Fish Pathol. 2010;30(4):152-158.

[45] Soto